Under the deal, Caputron will distribute the Neuro-MS/D Diagnostic, Therapeutic, and Advanced Therapeutic rTMS stimulators in the US and Canada.

Caputron Medical CEO Robin Azzam said: "The addition of the Neurosoft technologies to our broad neuromodulation product portfolio highlights Caputron Medical’s commitment to provide our customers with the best and highest value neuromodulation products.

"These products will complement our transcranial direct current stimulation (tDCS) and High Definition-tDCS systems provided through Soterix Medical and our broad range of neuromodulation accessories."

Neurosoft products are currently used at the medical research centres in the study of the non-invasive neuromodulation with applications areas, including psychiatry, neurology, cognitive neuroscience, clinical neurophysiology and rehabilitation.

Caputron noted that Neurosoft TMS systems feature a cooling system, which can perform up to 10,000 pulses during one session, a peak magnetic field of up to 4 Tesla and 20 Hz stimulation with 100% intensity.

Neurosoft chief medical officer Nickolay Smirnov said: "Distribution of industry leading Neurosoft TMS through Caputron Medical will further enhance customer support in the US."